Hepatic in vitro metabolism of etoperidone, an antidepressant drug, in the rat and human

Taiwan Pharmaceutical Journal

Volumn 59, Issue 1, 2007, Pages 31-38

  Wu, Wu Nan ^a   McKown, Linda A ^a  

^a JOHNSON AND JOHNSON PHARMACEUTICAL RESEARCH AND DEVELOPMENT   (United States)

Author keywords

Antidepressant drug; Etoperidone; In vitro metabolism; Metabolite identification; Rat and human hepatic S9 fractions

Indexed keywords

(3 CHLOROPHENYL)PIPERAZINE; ANTIDEPRESSANT AGENT; DRUG METABOLITE; ETOPERIDONE; REDUCED NICOTINAMIDE ADENINE DINUCLEOTIDE PHOSPHATE; TRIAZOLE PROPIONIC ACID; TRIAZOLE PROPYLALDEHYDE; UNCLASSIFIED DRUG;

ARTICLE; CONTROLLED STUDY; DEALKYLATION; DRUG METABOLISM; DRUG STRUCTURE; HUMAN; IN VITRO STUDY; LIVER METABOLISM; NONHUMAN; OXIDATION; RAT;

EID: 38549115096     PISSN: 10161015     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (15)

1. Ramacci, M. T.; Ghirardi, O.; Maccari, F.; Pacifici, L.; Sale, P. Pharmacological evaluation of δ2, 1,2,4-triazolin-5-one[1,3(4-m- chlorophenyl-1-piperazinyl)propyl]-3,4-diethyl-hydrochloride (etoperidone), a new potential antidepressant drug. Arzneim-Forsch. Drug Res., 1979, 29, 294-307.
2. Raffa, R. B.; Shank, R. P.; Vaught, J. Etoperidone, trazodone and MCPP: in vitro and in vivo identification of serotonin 5-HT1A (antagonist) activity. Psychopharmacology (Berlin), 1992, 108, 320-326.
3. Wu, W. N.; McKown, L. A. Recent advances in biotransformation of cns and cardiovascular agents. Curr. Drug Metab. 2002,1 , 255-170.
4. Brogden, R. N.; Heel, R. C.; Speight, T. M.; Avery, G. S. Trazodone, a review of its pharmacological properties and therapeutic use in depression and anxiety. Drugs, 1981, 21, 401-410.
5. th ed. McGraw-Hill, NY, ed. by Hardman, J. G.; Limbird, L. E.; Goodman Gilman, A., 2001, 269-288.
6. Holland, M. L.; Heebner, E. T. High-performance liquid chromatographic assay with ultraviolet detection for the determine of etoperidone and two active metabolites, 5-(1-hydroxyethyl)etoperidone and 1-(3-chlorophenyl)piperazine, in plasma. J. Chromatograpy. 1991, 567, 433-440.
7. th International Symposium on Pharmaceutical and Biomedical Analysis. 1993, #19.
8. Wu, W. N.; Masucci, J. A.; McKown, L. A.; Rodgers, J. D. Identification of four plasma metabolites of etoperidone in dogs. J. Pharm. & Biomed. Analy. 1995, 13, 177-184.
9. nd Ann. Meeting; Pharmacologist, 1991, 33, 208.
10. 14C] etoperidone in man. Xenobiotica, 2001, 31, 823-839.
11. Yan, Z.; Caldwell, G. W.; Wu, W. N.; McKown, L. A.; Rafferty, B.; Jones, W.; Masucci, J. A. In vitro identification of metabolic pathways and cytochrome P450 enzyme involved in the metabolism of etoperidone. Xenobiotica, 2002, 32, 949-962.
12. McKown, L. A.; Wu, W. N. In vitro metabolism of etoperidone in rat hepatic s9 fraction [abstract]. Experiment. Biolog. Meeting 1996; The FASEB J. 1996, 10, 3.
13. th Inter. ISSX Meeting 2001; Drug Metab. Rev. 2001, 33, 123.
14. Wu, W. N.; McKown, L. A.; Takacs, A. R.; Jones, W. J.; Reitz, A. B. Biotransformation of the antipsychotic agent, mazapertine, in dog-mass spectral characterization and identification of metabolites. Xenobiotica, 1999, 29, 453-466.
15. Wu, W. N.; McKown, L. A.; Reitz, A. B. Hepatic metabolism of the new antipsychotic agent, mazapertine, in rat - API-MS/MS identification of metabolites. Europ. J. Drug Metab. & Pharmacok. 2003, 30, 279-286.